In a report released on August 5, Sarah James from Barclays maintained a Buy rating on Alignment Healthcare (ALHC – Research Report), with a price target of $21.00. The company’s shares closed last Friday at $17.91.
According to TipRanks, James is a 5-star analyst with an average return of 13.1% and a 68.28% success rate. James covers the Healthcare sector, focusing on stocks such as DaVita, Acadia Healthcare, and Amedisys.
Currently, the analyst consensus on Alignment Healthcare is a Strong Buy with an average price target of $17.40, which is a (2.85)% downside from current levels. In a report released on August 5, Piper Sandler also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
The company has a one-year high of $23.35 and a one-year low of $6.14. Currently, Alignment Healthcare has an average volume of 436.5K.
Based on the recent corporate insider activity of 61 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ALHC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which they receive healthcare coverage and services on an annual basis.
Read More on ALHC:
